Merck, Samsung rack up data on Humira biosim, setting stage for approval apps

Industry watchers expect biosimilars for AbbVie's ($ABBV) Humira to be the most successful copycat biologics launched in the U.S. and Europe, and that's something Merck ($MRK) and Samsung are trying to get in on. Now, the biosim partners are one step closer, with their knockoff clearing late-stage trials and setting the stage for global regulatory applications. Report | More

Suggested Articles

FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.

Mylan is taking coronavirus support to Sesame Street, backing Sesame Workshop's ongoing work to help children and parents cope with the pandemic.

Opdivo's wins in front-line gastric and esophageal cancers comes a year after Merck's Keytruda flopped in the same setting.